Purpose Tumor-treating fields (TTFields) are an antimitotic treatment modality that interfere
with glioblastoma (GBM) cell division and organelle assembly by delivering low-intensity,
alternating electric fields to the tumor. A previous analysis from the pivotal EF-14 trial
demonstrated a clear correlation between TTFields dose density at the tumor bed and
survival in patients treated with TTFields. This study tests the hypothesis that the antimitotic
effects of TTFields result in measurable changes in the location and patterns of progression …